B-CELL APLASIA AFTER CAR-T
IVIG AND PROPHYLAXIS IN INDIA

CD19 is expressed not only on lymphoma and leukaemia cells but also on all normal B lymphocytes. When CAR-T cells destroy CD19-positive targets, they eliminate normal B cells too — a predictable on-target, off-tumour effect.

• On-Target Effect

  B-cell aplasia is not a complication — it is a pharmacodynamic marker that CAR-T cells are actively functioning. Persistent B-cell aplasia typically correlates with ongoing CAR-T cell activity and is associated with lower relapse rates.

• Duration with NexCAR19

  Median B-cell aplasia duration with NexCAR19 is approximately 6–12 months. Some patients recover B-cell populations earlier; others experience prolonged aplasia, particularly those in deep remission.

• Hypogammaglobulinaemia

  Without functioning B cells, antibody production falls. IgG typically drops below 500 mg/dL within 2–4 months of CAR-T infusion. This creates an infection vulnerability that is managed with IVIG replacement.

• Recovery

  B-cell recovery is detected by flow cytometry as CD19+ B cells re-emerging in peripheral blood. Once B cells recover and IgG normalises above 700 mg/dL, IVIG can be discontinued under physician guidance.

India is uniquely positioned for affordable IVIG replacement — with both branded imported products and cost-effective biosimilar IVIG available through hospital pharmacies and outpatient infusion centres.

• Branded IVIG Products

  Octagam (Octapharma) and Flebogamma (Grifols) are available at major Indian hospitals. These are established IVIG preparations used in the same centres performing CAR-T infusions.

• Biosimilar IVIG

  Biosimilar IVIG products manufactured in India are available at significantly lower cost — typically Rs 3,000–8,000 per 5g vial. For most CAR-T patients receiving 0.4–0.5 g/kg monthly, this makes long-term management feasible.

• India Cost vs USA

  IVIG infusion in India: Rs 5,000–15,000 per session (~$60–180). Same infusion in the USA: $1,500–2,500 per session. For a patient requiring monthly IVIG for 12 months, this represents a saving of $15,000–30,000.

• Home-Country IVIG Options

  International patients returning to Bangladesh, Kenya, Sri Lanka, or other home countries can often access IVIG locally — and in some cases at lower cost than India. CancerFax helps identify local infusion capacity before patients depart.

Patients completing CAR-T at TMC Mumbai can continue IVIG as an outpatient at any major Indian hospital network — allowing home-city management without returning to TMC.

• Apollo Hospitals Network

  Apollo has outpatient infusion centres across Chennai, Hyderabad, Delhi, Bangalore, and Kolkata. Day-care infusion bays for IVIG are available without overnight admission. Haematology follow-up can be arranged at the nearest Apollo centre.

• Kokilaben Dhirubhai Ambani Hospital

  Kokilaben in Mumbai (Andheri West — near TMC Parel) has dedicated haematology day care for infusion management including IVIG. Accessible for patients staying in the Mumbai area during the early post-CAR-T period.

• Manipal Hospitals

  Manipal's network covering Bangalore, Mangalore, Delhi, and Vijayawada provides outpatient haematology infusion services including IVIG. Good option for South India-based patients or those from Sri Lanka.

• Max Hospital

  Max Hospital in Delhi (Saket, Patparganj) has robust haematology and infusion services accessible for patients from North India, Nepal, Bangladesh, and Pakistan.

All patients receive a multi-drug prophylaxis regimen following CAR-T infusion to protect against bacterial, fungal, and viral infections during the immunosuppressed period.

1. 1

   Cotrimoxazole — PCP Prophylaxis

   Co-trimoxazole (trimethoprim-sulfamethoxazole) DS tablet given three times weekly or daily to prevent Pneumocystis jirovecii pneumonia. Continued until CD4 count recovers above 200 cells/μL.

2. 2

   Antifungal — Fluconazole or Itraconazole

   Fluconazole 100–200 mg daily or itraconazole 200 mg daily for Candida and moulds prophylaxis during the period of neutrophil and B-cell depletion.

3. 3

   Antiviral — Acyclovir or Valacyclovir

   Acyclovir 400 mg BD or valacyclovir 500 mg BD for HSV and VZV reactivation prophylaxis. CMV monitoring (PCR every 2 weeks) for high-risk patients.

4. 4

   Monthly IgG Monitoring

   Serum IgG level checked monthly. If IgG falls below 400–500 mg/dL or patient develops recurrent infections, IVIG infusion at 0.4–0.5 g/kg is administered.

5. 5

   Vaccination (Delayed)

   Live vaccines are contraindicated until B-cell recovery. Non-live vaccines (influenza, pneumococcal, COVID-19 booster) may be given after B-cell recovery is confirmed by flow cytometry.

• 6–12 moMedian Duration of B-Cell Aplasia with NexCAR19Most patients recover normal B-cell populations within 12 months; some experience prolonged aplasia consistent with sustained CAR-T activity.
• < 500 mg/dLIgG Threshold Requiring IVIGIgG below 500 mg/dL is the standard threshold for initiating IVIG replacement at most Indian CAR-T centres.
• $60–180IVIG Infusion Cost in IndiaPer-session IVIG cost in India (Rs 5,000–15,000) — compared to $1,500–2,500 per session in the USA.
• MonthlyIgG Monitoring FrequencySerum IgG should be checked monthly during the aplasia period to guide IVIG dosing decisions.

Most international CAR-T patients return home 3–6 weeks after infusion. Managing B-cell aplasia in a home country setting requires planning before departure from India.

• Pre-Departure Checklist

  Before leaving India: ensure discharge summary includes prophylaxis regimen, IgG threshold for IVIG, monitoring schedule, and emergency contact at TMC. CancerFax provides a formatted handover letter for the home-country haematologist.

• IVIG in Home Country

  IVIG is available in most East African and South Asian countries, though brand availability and cost vary. CancerFax identifies local infusion capacity in Nairobi, Dhaka, Colombo, and other cities before patients depart.

• Telemedicine Follow-Up

  TMC and Apollo offer telemedicine consultations for post-CAR-T follow-up. CancerFax facilitates the telemedicine link between the home-country treating physician and the Indian CAR-T team.

• When to Return to India

  Return visits to India are typically not required unless the patient develops grade 3–4 infection, confirmed relapse, or requires a bone marrow assessment. Most monitoring is manageable remotely.

Continue exploring CAR-T management in India — from CRS and ICANS to the full treatment timeline and access pathway.

Frequently Asked Questions — B-Cell Aplasia After CAR-T